Liraglutide for HIV-associated Neurocognitive Disorder
NCT02743598 on ClinicalTrials.gov · last registry update 2022-07-29
Stopped early, having planned 4 participants. The sponsor logged completion for 1 June 2018. Primary outcome, as filed: Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile. liraglutide is approved in the US, but not for metabolic syndrome — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- TERMINATED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Temple University
- Sponsor type
- Other
- Enrollment
- 4
- Started
- 2016-09
- Primary completion
- 2018-06-01 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile
Conditions studied
HIV Infection · Diabetes Mellitus Type 2 · Obesity · Overweight · Metabolic Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.